Skip to main content

Market Overview

UPDATE: Stifel Downgrades ViroPharma Following News of Proposed Acquisition by Shire Pharmaceuticals


In a report published Tuesday, Stifel analyst Stephen Willey downgraded the rating on ViroPharma (NASDAQ: VPHM) from Buy to Hold, and removed the $47.00 price target.

In the report, Stifel noted, “We are downgrading shares of Viropharma Inc. as a result of the company's recent announcement that its Board of Directors have unanimously agreed to a proposed acquisition by Shire Pharmaceuticals (SHPG: $135.01, Not Covered). We believe the proposed acquisition price of $50/share fairly values the company, we do not expect any additional bidders to emerge, and we expect the deal to close by YE13 without any concerns on the manufacturing or antitrust fronts.”

ViroPharma closed on Monday at $49.48.

Latest Ratings for VPHM

Nov 2013Stifel NicolausDowngradesBuyHold
Nov 2013JP MorganDowngradesOverweightNeutral
Nov 2013PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for VPHM
View the Latest Analyst Ratings


Related Articles (VPHM)

View Comments and Join the Discussion!

Posted-In: Stephen Willey StifelAnalyst Color Downgrades Analyst Ratings

Latest Ratings

FIBKStephens & Co.Downgrades
LEAFCanaccord GenuityDowngrades8.5
AGMSidoti & Co.Downgrades115.0
KEXGabelli & Co.Downgrades
OCGNCantor FitzgeraldDowngrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at